Rakuten Medical

Executive Summary

Rakuten Medical is a global biotechnology company advancing its Alluminox™ platform, a precision photoimmunotherapy technology designed to induce rapid and selective cell killing. The company is currently in Phase 3 clinical development for its lead candidate, targeting solid tumors such as head and neck cancer. By leveraging a light-activated antibody-drug conjugate, Alluminox aims to improve efficacy while reducing systemic toxicity compared to conventional therapies. With a strong scientific foundation and progressing clinical pipeline, Rakuten Medical represents a promising opportunity in the immuno-oncology space. The company operates out of San Diego, California, and has been in operation since 2010, focusing on biologics and antibody-based therapeutics.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Top-Line Data Readout for Alluminox in Head and Neck Cancer55% success
• Q2 2027BLA Submission for Alluminox50% success
• Q3 2026Strategic Partnership or Licensing Deal for Alluminox Platform40% success